US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,467.14

-3.0465-0.21%

Number of Gainers:10

Number of Losers:10

Number of Flat:- -

PE:- -

High:1,469.90

Open:1,469.76

Low:1,454.86

Close:1,470.19

Loading ...

Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug

MT Newswires Live

1 Stock Down 43% That Looks Too Cheap to Ignore

Lakeland Fire + Safety to Attend the 37th Annual Roth Conference

Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115

THOMSON REUTERS

BRIEF-Cadrenal Therapeutics Announces Collaboration Agreement With Abbott

Five Years Since Covid-19: Revisiting Indonesia's Response and Jokowi's Lockdown Rejection

Cadrenal Therapeutics Inc - Abbott to Share Insights From Heartmate 3 Trials

THOMSON REUTERS

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

ACCESS Newswire

Abbott : Citigroup Raises Target Price to $160 From $135

THOMSON REUTERS

Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Simply Wall St.

Citi ups Abbott target, opens ‘negative catalyst watch’

Bertrandt AG Managerial Share Purchase Signals Confidence

AstraZeneca (AZN) Receives a Buy from Bernstein

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1467.1393,"timestamp":1741294799999,"preClose":1470.1858,"halted":0,"volume":105471886,"delay":0,"changeRate":-0.002072,"change":-3.046509,"pbRate":4.026038,"amount":5675719740.654533,"amplitude":0.01023,"prevYearClose":1274.8187,"fiveDayClose":1446.7607,"twentyDayClose":1373.9138,"turnoverRate":0.00682,"marketCap":1210199793589.5,"floatMarketCap":1188113526137,"peRate":31.895692},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1469.9016,"amplitude":0.01023,"preClose":1470.1858,"low":1454.8619,"pbRate":"4.026038","latestPrice":1467.1393,"volume":105471886,"delay":0,"open":1469.7611,"prevYearClose":1274.8187,"prevWeekClose":1463.5875,"prevMonthClose":1463.5875,"prevQuarterClose":1274.8187,"fiveDayClose":1446.7607,"twentyDayClose":1373.9138,"sixtyDayClose":1299.5834,"secType":"PLATE","market":"US","turnoverRate":0.00682,"peRate":31.895692,"marketCap":1210199793589.5,"floatMarketCap":1188113526137,"timestamp":1741294799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":10,"down":10,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:16,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516679026","title":"Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516679026","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516679026?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:47","pubTimestamp":1741096056,"startTime":"0","endTime":"0","summary":"Cadrenal Therapeutics  said Tuesday it has signed a collaboration agreement with Abbott  to support a trial of its tecarfarin anticoagulation and hemocompatibility with left ventricular assist devices.Financial terms were not disclosed.Under the terms of the agreement, Abbott will support Cadrenal on the planning and execution of the trial to evaluate the efficacy and safety of tecarfarin in patients with left ventricular assist devices.Abbott will also share insights from recent trials and will support Cadrenal with trial design, site identification, trial awareness, and expertise.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CVKD","BK4139","ABT.AU","LU1691799644.USD","LU2112291526.USD","BK4007","BK4533","LU1989763427.SGD","LU1057294990.SGD","LU2237957902.USD","LU0170899867.USD","IE0002141913.USD","LU2237957811.SGD","SGXZ23171101.USD","LU1989763690.USD","IE00BJJMRZ35.SGD","BK4566","LU0266013472.USD","BK4581","ABT","LU1023059063.AUD","LU2089984988.USD","SG9999004303.SGD","LU1721429741.USD","IE00BJT1NW94.SGD","LU0234572021.USD","SG9999002232.USD","LU0868494617.USD","LU0122379950.USD","LENZ","SG9999002224.SGD","LU1914381329.SGD","BK4082","IE00B2B36J28.USD","BK4504","BK4568","IE00BFTCPJ56.SGD","BK4585","BK4588","LU1721429402.USD","LU2133065610.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU2468319806.SGD","BK4592","LU1061106388.HKD"],"gpt_icon":0},{"id":"2516901677","title":"1 Stock Down 43% That Looks Too Cheap to Ignore","url":"https://stock-news.laohu8.com/highlight/detail?id=2516901677","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516901677?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:45","pubTimestamp":1741095900,"startTime":"0","endTime":"0","summary":"After all this time, Pfizer's coronavirus portfolio is still performing relatively well.The drumaker has an impressive pipeline that should lead to plenty of brand-new drugs.The stock's valuation looks attractive, and it offers a generous dividend yield.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/04/1-stock-down-43-that-looks-too-cheap-to-ignore/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4550","SG9999003800.SGD","BK4581","LU1894683348.USD","BK4588","LU0225771236.USD","BK4533","LU0868494617.USD","SG9999013999.USD","LU0058720904.USD","LU1894683264.USD","SG9999001176.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU0321505439.SGD","LU0289739699.SGD","SG9999001176.SGD","BK4007","IE00B19Z3B42.SGD","IE0002270589.USD","LU0321505868.SGD","LU1066053197.SGD","IE00B19Z3581.USD","BK4568","BK4534","LU0306807586.USD","IE00BLSP4239.USD","LU1023059063.AUD","LU1883839398.USD","SG9999002224.SGD","LU0170899867.USD","BK4585","LU0122379950.USD","BK4592","SGXZ57979304.SGD","LU1057294990.SGD","BK4599","LU0985481810.HKD","LU0306806265.USD","PFE","IE000M9KFDE8.USD","LU0456855351.SGD","LU1066051498.USD","SG9999002232.USD","SG9999011175.SGD","IE00BBT3K403.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"2516253679","title":"Lakeland Fire + Safety to Attend the 37th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516253679","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516253679?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:31","pubTimestamp":1741095060,"startTime":"0","endTime":"0","summary":"Company to Participate in a Panel Discussion March 17 and a Hosted Fireside Chat March 18. HUNTSVILLE, Ala., March 04, 2025  -- Lakeland Industries, Inc.  , a leading global manufacturer of protective clothing for industry, healthcare, and first responders, today announced that management will attend the 37th Annual Roth Conference being held at The Laguna Cliffs Marriott Resort & Spa in Dana Point, CA March 16-18, 2025.37th Annual Roth Conference Date: March 16-18, 2025Location: The Laguna Cliffs Marriott Resort & Spa, Dana Point, CAFormat: In-person 1x1 MeetingsAttendees: Chief Executive Officer and Executive Chairman Jim Jenkins and Chief Financial Officer Roger ShannonConference Website: Click here. Fireside ChatDate: Tuesday, March 18, 2025Time: 9:30 AM PTLocation: GREEN – DANA 6Participants: Chief Executive Officer and Executive Chairman Jim Jenkins and Chief Financial Officer Roger ShannonWebcast: Click here. For more information about the 37th Annual Roth Conference, or to sche","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lakeland-fire-safety-attend-37th-133100660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B66KJ199.SGD","IE00B7SZL793.SGD","LAKE","BK4568","IE00B19Z4B17.USD","BK4202","IE0031619046.USD"],"gpt_icon":0},{"id":"2516676930","title":"Gilead Sciences, Inc. : Oppenheimer Raises Target Price to $132 From $115","url":"https://stock-news.laohu8.com/highlight/detail?id=2516676930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516676930?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:15","pubTimestamp":1741094114,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nAZN3HPGL5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4578","IE00B7SZLL34.SGD","LU2089984988.USD","BK4566","LU1066053197.SGD","IE00BZ1G4Q59.USD","IE00B19Z3581.USD","LU1839511570.USD","LU0289739699.SGD","GILD","LU0234570918.USD","LU2087621335.USD","BK4585","IE00BKVL7J92.USD","BK4583","BK4568","LU2468319806.SGD","LU1585245621.USD","LU0058720904.USD","LU1066051498.USD","LU0109394709.USD","LU0320765992.SGD","BK4588","IE00BSNM7G36.USD","BK4532","LU1571399168.USD","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B3T34201.USD","LU0889565916.HKD","BK4139","BK4550","LU1430594728.SGD"],"gpt_icon":0},{"id":"2516167696","title":"BRIEF-Cadrenal Therapeutics Announces Collaboration Agreement With Abbott","url":"https://stock-news.laohu8.com/highlight/detail?id=2516167696","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516167696?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:14","pubTimestamp":1741094067,"startTime":"0","endTime":"0","summary":"BRIEF-Cadrenal Therapeutics Announces Collaboration Agreement With Abbott March 4 (Reuters) - Cadrenal Therapeutics Inc CVKD.O:CADRENAL THERAPEUTICS ANNOUNCES COLLABORATION AGREEMENT WITH ABBOTT IN SU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA76BCYD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU1989763427.SGD","BK4007","BK4585","LU1061106388.HKD","LU2468319806.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU2237957811.SGD","BK4082","IE00B4R5TH58.HKD","LU0122379950.USD","LU0234572021.USD","SGXZ23171101.USD","CVKD","LU2133065610.SGD","LU1721429741.USD","BK4581","BK4533","BK4566","BK4568","LU0266013472.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","BK4588","LU1914381329.SGD","LU1989763690.USD","LU2089984988.USD","LU1691799644.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0170899867.USD","IE00BJT1NW94.SGD","SG9999004303.SGD","LU2237957902.USD","ABT","SG9999002232.USD","LU2112291526.USD","BK4504","LU0868494617.USD","BK4592","SG9999002224.SGD","LU1721429402.USD"],"gpt_icon":0},{"id":"2516567288","title":"Five Years Since Covid-19: Revisiting Indonesia's Response and Jokowi's Lockdown Rejection","url":"https://stock-news.laohu8.com/highlight/detail?id=2516567288","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516567288?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:08","pubTimestamp":1741093726,"startTime":"0","endTime":"0","summary":"The cost is lower compared to the economic losses. Once a lockdown succeeds, the economy can grow more solidly. We are in an emergency, yet the policies are half-hearted,\" Bhima toldTempoon June 24, 2021, believing the government still had the capacity to enforce a lockdown.Jokowi’s Ministers Fail to Contain Covid-19Coordinating Minister for Maritime Affairs and Investment Luhut Binsar Pandjaitan faced heavy criticism for his pandemic mitigation policies. As coordinator of the Public Activity Restrictions , Luhut made contradictory statements about the government’s Covid-19 response.At one point, Luhut claimed that the situation was under control during the implementation of the Java-Bali emergency PPKM, which had been in effect for ten days\"If anyone says the situation is out of control, that is completely the opposite. Those who say it is uncontrolled can come to me, and I’ll show them to their faces that we have it under control,\" Luhut said in an online press conference on Monday, ","market":"fut","thumbnail":"https://statik.tempo.co/data/2020/03/23/id_925301/925301_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2020/03/23/id_925301/925301_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1982515/five-years-since-covid-19-revisiting-indonesias-response-and-jokowis-lockdown-rejection","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4139","BNTX","BK4588","BK4535","BK4551","BK4548","BK4585","BK4568"],"gpt_icon":0},{"id":"2516754306","title":"Cadrenal Therapeutics Inc - Abbott to Share Insights From Heartmate 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2516754306","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516754306?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA76BCYD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1057294990.SGD","CVKD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU2237957902.USD","LU1989763690.USD","LU2089984988.USD","LU0266013472.USD","IE0002141913.USD","LU1061106388.HKD","LU2468319806.SGD","BK4568","BK4007","BK4082","LU1721429741.USD","LU1914381329.SGD","LU1691799644.USD","LU1989763427.SGD","ABT","BK4504","IE00BJJMRZ35.SGD","SG9999002232.USD","LU1023059063.AUD","IE00B2B36J28.USD","LU2133065610.SGD","SG9999004303.SGD","LU1721429402.USD","IE0009355771.USD","BK4533","LU2237957811.SGD","BK4581","LU2112291526.USD","LU0868494617.USD","LU0122379950.USD","BK4585","IE00B4R5TH58.HKD","BK4566","SG9999002224.SGD","SGXZ23171101.USD","LU0170899867.USD","BK4588","BK4592","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2516667640","title":"Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD","url":"https://stock-news.laohu8.com/highlight/detail?id=2516667640","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516667640?lang=en_us&edition=fundamental","pubTime":"2025-03-04 21:00","pubTimestamp":1741093200,"startTime":"0","endTime":"0","summary":"Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3 LVAD patients. PONTE VEDRA, Fla., March 04, 2025----Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist , today announced the signing of a Collaboration Agreement with Abbott  to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices  trial.\"We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enrollment efforts,\" said Quang X. Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. \"Together, we have a unique opportunit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cadrenal-therapeutics-announces-collaboration-agreement-130000984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU0170899867.USD","LU2237957811.SGD","LU1721429402.USD","IE00BJT1NW94.SGD","BK4585","LU2089984988.USD","BK4566","BK4588","IE0009355771.USD","SG9999002224.SGD","LU2237957902.USD","LU1691799644.USD","BK4183","IE0002141913.USD","IE00B2B36J28.USD","BK4082","LU0234572021.USD","LU1057294990.SGD","LENZ","ABT","LU2133065610.SGD","IE00B4R5TH58.HKD","LU0266013472.USD","LU1989763427.SGD","LU2112291526.USD","BK4504","IE00BFTCPJ56.SGD","LU1989763690.USD","BK4581","LU1023059063.AUD","LU2468319806.SGD","CVKD","SG9999004303.SGD","ODD","BK4533","LU1061106388.HKD","BK4007","SG9999002232.USD","LU1721429741.USD","BK4139","LU1914381329.SGD","BK4568","BK4592","LU0868494617.USD"],"gpt_icon":0},{"id":"2516620121","title":"CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516620121","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516620121?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:00","pubTimestamp":1741089600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., March 4, 2025 /PRNewswire/ -- CalciMedica Inc.  , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium  channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announcedthat Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, delivered a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference  on March 3, 2025 in San Diego, CA. The presentation outlined the role of CRAC channels in acute kidney injury  pathophysiology and included new data highlighting the potential of CalciMedica's lead product candidate, Auxora, in AKI. CalciMedica is currently conducting a Phase 2 trial of Auxora in patients with Stage 2 or Stage 3 AKI and acute hypoxemic respiratory failure, which is expected to read out in 2025.In clinical trial biomarker studies, CARDEA patients who received Auxora versus placebo had","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/calcimedica-presents-aki-data-post-120000286.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/calcimedica-presents-aki-data-post-120000286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","POST","BK4535","BK4006","CALC","BK4588","BK4212","BK4568","BK4551","BNTX","BK4548","AP","BK4139","BK4007"],"gpt_icon":0},{"id":"2516271126","title":"Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan","url":"https://stock-news.laohu8.com/highlight/detail?id=2516271126","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516271126?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:30","pubTimestamp":1741087800,"startTime":"0","endTime":"0","summary":"SHELTON, CT / ACCESS Newswire / March 4, 2025 / The HHS Department Secretary Robert F. Kennedy Jr. wrote an Opinion piece in the FoxNews entitled \"Measles outbreak is call to action for all of us\". He identifies an important issue that, \"…there is no approved antiviral for those who may be infected…\"We applaud Secretary Kennedy for recognizing the urgency of the situation and taking all possible steps including promoting vaccination in response to this outbreak, while clearly recognizing the deficiency in the response to be the lack of an effective treatment for measles viral disease,\" said Anil R. Diwan, PhD., President of NanoViricides, Inc.We note that the current efforts at containment with case-tracking, contact-tracing and isolation, face daunting challenges to be effective because measles is far more contagious than SARS-CoV-2 that caused the global COVID pandemic. In fact, measles is the most contagious disease known to humans. Also, a person may be contagious several days befo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/measles-outbreak-nv-387-promises-113000537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","BK4139","NNVC","BK4009","HHS"],"gpt_icon":0},{"id":"2516622883","title":"Abbott : Citigroup Raises Target Price to $160 From $135","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516622883?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:13","pubTimestamp":1741086823,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN05D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1721429741.USD","LU2089984988.USD","LU0868494617.USD","BK4566","IE0002141913.USD","LU2133065610.SGD","LU2237957902.USD","SG9999002232.USD","BK4581","BK4504","LU2112291526.USD","IE00BJT1NW94.SGD","BK4585","LU2237957811.SGD","IE00BFTCPJ56.SGD","LU1989763427.SGD","BK4568","IE0009355771.USD","BK4082","LU2468319806.SGD","LU1914381329.SGD","LU1721429402.USD","ABT","SG9999002224.SGD","LU1691799644.USD","BK4588","BK4592","LU1061106388.HKD","LU0170899867.USD","LU0234572021.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU0266013472.USD","LU1023059063.AUD","LU1989763690.USD","SG9999004303.SGD","LU0122379950.USD","LU1057294990.SGD","BK4533"],"gpt_icon":0},{"id":"2516627913","title":"Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516627913","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516627913?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:00","pubTimestamp":1741086021,"startTime":"0","endTime":"0","summary":"Abbott Laboratories'  stock is up by a considerable 21% over the past three months. Since the market usually pay for a company’s long-term fundamentals, we decided to study the company’s key performance indicators to see if they could be influencing the market. In this article, we decided to focus on Abbott Laboratories'  ROE.Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Abbott Laboratories is:. A Side By Side comparison of Abbott Laboratories' Earnings Growth And 28% ROE. Is Abbott Laboratories Using Its Retained Earnings Effectively?The high three-year median payout ratio of 59%  for Abbott Laboratories suggests that the company's growth wasn't really hampered despite it returning most of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbott-laboratories-nyse-abt-stocks-110021096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","IE00BJJMRZ35.SGD","SGXZ23171101.USD","LU0170899867.USD","LU2237957811.SGD","LU1721429402.USD","IE00BJT1NW94.SGD","BK4585","LU2089984988.USD","BK4566","BK4588","IE0009355771.USD","SG9999002224.SGD","LU2237957902.USD","LU1691799644.USD","IE0002141913.USD","IE00B2B36J28.USD","BK4082","LU0234572021.USD","LU1057294990.SGD","ABT","LU2133065610.SGD","IE00B4R5TH58.HKD","LU0266013472.USD","LU1989763427.SGD","LU2112291526.USD","BK4504","IE00BFTCPJ56.SGD","LU1989763690.USD","NYSE","BK4581","LU1023059063.AUD","LU2468319806.SGD","SG9999004303.SGD","BK4533","LU1061106388.HKD","SG9999002232.USD","LU1721429741.USD","LU1914381329.SGD","BK4568","BK4592","LU0868494617.USD"],"gpt_icon":0},{"id":"2516621292","title":"Citi ups Abbott target, opens ‘negative catalyst watch’","url":"https://stock-news.laohu8.com/highlight/detail?id=2516621292","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516621292?lang=en_us&edition=fundamental","pubTime":"2025-03-04 18:40","pubTimestamp":1741084851,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Abbott (ABT) to $160 from $135 and keeps a Buy rating on the shares. The analyst also added a “90-day negati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-ups-abbott-target-opens-negative-catalyst-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-ups-abbott-target-opens-negative-catalyst-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1057294990.SGD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU2237957902.USD","LU1989763690.USD","LU2089984988.USD","LU0266013472.USD","IE0002141913.USD","LU1061106388.HKD","LU2468319806.SGD","BK4568","BK4082","LU1721429741.USD","LU1914381329.SGD","LU1691799644.USD","LU1989763427.SGD","ABT","BK4504","IE00BJJMRZ35.SGD","SG9999002232.USD","LU1023059063.AUD","IE00B2B36J28.USD","LU2133065610.SGD","SG9999004303.SGD","LU1721429402.USD","IE0009355771.USD","BK4533","LU2237957811.SGD","BK4581","LU2112291526.USD","LU0868494617.USD","LU0122379950.USD","BK4585","IE00B4R5TH58.HKD","BK4566","SG9999002224.SGD","SGXZ23171101.USD","LU0170899867.USD","BK4588","BK4592","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2516664076","title":"Bertrandt AG Managerial Share Purchase Signals Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2516664076","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516664076?lang=en_us&edition=fundamental","pubTime":"2025-03-04 16:57","pubTimestamp":1741078652,"startTime":"0","endTime":"0","summary":"Bertrandt ( ($DE:BDT) ) has shared an update. Bertrandt AG announced a managerial transaction involving Dr. Andreas Fink, a member of the managing ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bertrandt-ag-managerial-share-purchase-signals-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bertrandt-ag-managerial-share-purchase-signals-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTX","BK4548","BK4535","BK4551","BK4210","BK4585","BK4139","AG","BK4588","BK4568"],"gpt_icon":0},{"id":"2516864148","title":"AstraZeneca (AZN) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2516864148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516864148?lang=en_us&edition=fundamental","pubTime":"2025-03-04 15:56","pubTimestamp":1741074975,"startTime":"0","endTime":"0","summary":"In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of £190...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-buy-from-bernstein?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/astrazeneca-azn-receives-a-buy-from-bernstein?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU2456880835.USD","LU0109394709.USD","LU0889565916.HKD","BK4568","LU1829250122.USD","LU2236285917.USD","LU2417539215.USD","LU2462157665.USD","LU0320765992.SGD","BK4585","BK4588","AZN"],"gpt_icon":0},{"id":"2516958616","title":"Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2516958616","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516958616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:50","pubTimestamp":1741042206,"startTime":"0","endTime":"0","summary":"In the latest market close, Gilead Sciences  reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow experienced a drop of 1.48%, and the technology-dominated Nasdaq saw a decrease of 2.64%.The HIV and hepatitis C drugmaker's shares have seen an increase of 17.6% over the last month, surpassing the Medical sector's gain of 1.11% and the S&P 500's loss of 1.26%.The upcoming earnings release of Gilead Sciences will be of great interest to investors. The company's earnings per share  are projected to be $1.73, reflecting a 231.06% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $6.78 billion, indicating a 1.36% growth compared to the corresponding quarter of the prior year.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research show","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-gild-rises-market-225006380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","BK4588","BK4578","LU0109394709.USD","LU1839511570.USD","LU0234570918.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0289739699.SGD","LU2468319806.SGD","BK4583","LU2089984988.USD","GILD","BK4566","IE00B19Z3B42.SGD","IE0002270589.USD","LU1066053197.SGD","LU0320765992.SGD","LU2087621335.USD","IE00B19Z3581.USD","IE00B3T34201.USD","BK4532","BK4568","LU1585245621.USD","LU0889565916.HKD","LU1430594728.SGD","IE00BSNM7G36.USD","BK4585","LU1571399168.USD","BK4139","IE00BKVL7J92.USD","LU1066051498.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":20,"pageCount":6,"totalSize":318}]}}